Vivo Bio Tech (VIVOBIOT)₹14.74−0.34%Biotechnology
In the Jun 2026 quarter (consolidated), Vivo Bio Tech reported sales of ₹14.25 Cr, up 14.2% from Jun 2025, and net profit of ₹0.20 Cr, down 85.2% year on year. For the year to Mar 2026, sales were ₹53.20 Cr and net profit −₹1.72 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 9.24 | 12.83 | 11.75 | 10.11 | 12.02 | 12.18 | 12.26 | 12.48 | 13.07 | 13.49 | 14.17 | 14.25 |
| Expenses | 4.41 | 6.50 | 6.41 | 5.79 | 6.48 | 6.69 | 7.30 | 7.06 | 7.72 | 8.05 | 9.79 | 9.27 |
| Operating Profit | 4.88 | 6.39 | 5.39 | 4.38 | 5.61 | 5.56 | 5.04 | 5.50 | 5.44 | 5.51 | 4.47 | 5.07 |
| OPM % | 52.5% | 49.6% | 45.7% | 43.1% | 46.4% | 45.4% | 40.8% | 43.8% | 41.4% | 40.7% | 31.4% | 35.4% |
| Other Income | 0.00 | 0.02 | 0.00 | 0.00 | 4.61 | 0.00 | 0.14 | 0.13 | 0.12 | 0.13 | 0.02 | 0.05 |
| Interest | 2.08 | 2.21 | 1.51 | 1.91 | 2.05 | 1.83 | 1.67 | 1.49 | 1.46 | 1.39 | 1.47 | 1.23 |
| Depreciation | 2.31 | 2.29 | 2.44 | 2.24 | 2.30 | 2.26 | 2.26 | 2.65 | 2.58 | 2.67 | 2.76 | 3.54 |
| Profit before tax | 0.48 | 1.91 | 1.44 | 0.23 | 5.88 | 1.47 | 1.25 | 1.49 | 1.52 | 1.58 | 0.26 | 0.35 |
| Tax % | 29.8% | 31.0% | 48.9% | 27.2% | 10.7% | 43.8% | 14.5% | 9.4% | 42.4% | 20.3% | 2,164.0% | 44.1% |
| Net Profit | 0.34 | 1.33 | 0.75 | 0.18 | 5.24 | 0.83 | 1.07 | 1.35 | 0.88 | 1.26 | −5.17 | 0.20 |
| EPS (Rs) | 0.23 | 0.90 | 0.51 | 0.12 | 3.52 | 0.52 | 0.63 | 0.68 | 0.40 | 0.58 | −2.34 | 0.10 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 28.53 | 34.09 | 46.95 | 55.73 | 55.23 | 51.71 | 51.30 | 52.12 | 45.39 | 46.56 | 53.20 | 54.98 |
| Expenses | 24.98 | 26.61 | 36.27 | 46.53 | 43.05 | 34.12 | 35.42 | 30.49 | 24.27 | 26.21 | 31.95 | 34.83 |
| Operating Profit | 3.73 | 7.65 | 10.93 | 9.54 | 12.51 | 17.85 | 16.15 | 21.93 | 21.34 | 20.64 | 21.60 | 20.49 |
| OPM % | 13.0% | 22.3% | 23.1% | 17.0% | 22.5% | 34.4% | 31.3% | 41.8% | 46.8% | 44.0% | 40.3% | 37.3% |
| Other Income | 0.88 | 0.39 | 0.12 | 0.00 | 0.04 | 0.07 | 0.09 | 0.03 | 0.03 | 4.78 | −0.15 | 0.32 |
| Interest | 0.46 | 1.28 | 2.36 | 2.63 | 3.09 | 3.66 | 4.26 | 7.98 | 7.94 | 7.54 | 5.90 | 5.55 |
| Depreciation | 3.36 | 3.91 | 4.65 | 5.07 | 5.18 | 5.60 | 7.46 | 9.29 | 9.30 | 9.04 | 10.65 | 11.55 |
| Profit before tax | 0.79 | 2.84 | 4.02 | 1.83 | 4.26 | 8.63 | 4.48 | 4.63 | 4.07 | 8.80 | 4.82 | 3.71 |
| Tax % | −16.7% | 11.6% | 21.9% | −23.2% | −4.5% | 34.1% | 50.8% | 42.6% | 37.9% | 17.1% | 135.5% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.02 | 0.00 | — |
| Net Profit | 0.92 | 2.51 | 3.13 | 2.26 | 4.45 | 5.69 | 2.21 | 2.66 | 2.54 | 7.30 | −1.72 | −2.83 |
| EPS (Rs) | 0.98 | 2.68 | 3.18 | 1.83 | 3.46 | 4.24 | 1.55 | 1.79 | 1.71 | 4.26 | −0.78 | −1.26 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9.36 | 9.36 | 9.36 | 9.84 | 12.36 | 12.89 | 13.42 | 14.25 | 14.89 | 14.89 | 17.16 | 22.19 |
| Reserves | −0.19 | 0.72 | 3.23 | 9.48 | 14.92 | 20.14 | 29.11 | 32.86 | 36.97 | 39.47 | 60.79 | 70.98 |
| Borrowings | 5.70 | 16.93 | 27.08 | 25.15 | 21.71 | 24.38 | 30.98 | 67.45 | 62.43 | 73.06 | 54.01 | 67.42 |
| Other Liabilities | 26.57 | 18.66 | 11.44 | 15.06 | 6.34 | 6.26 | 6.00 | 7.88 | 8.73 | 9.63 | 11.25 | 17.81 |
| Total Liabilities | 41.44 | 45.67 | 51.11 | 59.53 | 55.33 | 63.67 | 79.51 | 122 | 123 | 137 | 143 | 178 |
| Fixed Assets | 19.68 | 23.53 | 28.55 | 27.65 | 30.00 | 34.94 | 52.00 | 95.09 | 88.83 | 80.27 | 88.21 | 123 |
| CWIP | 0.06 | 0.03 | 2.95 | 3.93 | 0.06 | 0.14 | 0.31 | 0.86 | 1.89 | 9.18 | 12.79 | 4.79 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 21.90 |
| Other Assets | 21.70 | 22.11 | 19.61 | 27.95 | 25.27 | 28.59 | 27.20 | 26.49 | 32.30 | 47.60 | 42.21 | 28.72 |
| Inventories | 4.68 | 4.07 | 4.55 | 7.58 | 8.23 | 10.57 | 13.27 | 9.80 | 7.96 | 8.76 | 7.78 | 8.14 |
| Trade receivables | 4.32 | 3.83 | 7.68 | 11.80 | 8.43 | 10.50 | 7.30 | 12.04 | 12.40 | 11.81 | 11.27 | 11.77 |
| Cash & equivalents | 10.55 | 11.84 | 1.18 | 4.14 | 0.55 | 1.02 | 1.16 | 1.70 | 1.36 | 1.38 | 1.27 | 1.43 |
| Total Assets | 41.44 | 45.67 | 51.11 | 59.53 | 55.33 | 63.67 | 79.51 | 122 | 123 | 137 | 143 | 178 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 2.24 | 8.80 | −5.65 | 11.10 | −0.77 | 8.60 | 14.17 | 16.65 | 14.82 | 15.51 | 11.82 | 34.94 |
| Cash from investing activity | −2.03 | −7.19 | −11.82 | −4.71 | −3.52 | −10.22 | −22.77 | −51.02 | −3.99 | −7.94 | −15.81 | −59.25 |
| Cash from financing activity | −0.88 | −0.33 | 6.82 | −3.42 | 0.71 | 2.08 | 8.77 | 34.99 | −11.17 | −7.55 | 3.89 | 24.56 |
| Net cash flow | −0.67 | 1.29 | −10.68 | 2.95 | −3.58 | 0.46 | 0.13 | 0.54 | −0.33 | 0.00 | −0.12 | 0.14 |
| Capex | 2.05 | 7.21 | 11.85 | 4.71 | 3.52 | 10.24 | 22.83 | 51.10 | 4.01 | 7.94 | 22.28 | 37.43 |
| Free cash flow | 0.22 | 1.60 | −17.49 | 6.38 | −4.32 | −1.63 | −8.63 | −34.44 | 10.84 | 7.56 | −4.00 | −2.52 |
| CFO / OP % | 80.9% | 234.0% | −70.1% | 109.9% | −13.1% | 67.9% | 95.9% | 117.9% | 76.9% | 80.0% | 64.9% | 165.9% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 88 | 49 | 82 | 91 | 55 | 69 | 51 | 85 | 87 | 95 | 88 | 80 |
| Inventory days | 559 | 170 | 205 | 290 | 257 | 452 | 673 | 314 | 431 | 832 | 492 | 367 |
| Days payable | 815 | 364 | 243 | 305 | 153 | 168 | 71 | 75 | 52 | 101 | 63 | 89 |
| Cash conversion cycle | −167 | −144 | 45 | 78 | 160 | 355 | 654 | 325 | 467 | 827 | 518 | 359 |
| Working capital days | −353 | −130 | 20 | −12 | 37 | 36 | 30 | 9 | 39 | 65 | 101 | −21 |
| ROCE % | 4.7% | 5.9% | 12.3% | 15.1% | 9.5% | 13.8% | 18.8% | 9.3% | 11.0% | 9.9% | 9.0% | 7.7% |
For the Jun 2026 quarter, Vivo Bio Tech reported sales of ₹14.25 Cr, up 14.2% year on year and net profit of ₹0.20 Cr, down 85.2% year on year. The operating margin was 35.4%.
Vivo Bio Tech's sales for the year to Mar 2026 were ₹53.20 Cr; over the last twelve months they were ₹54.98 Cr.
Net profit for the year to Mar 2026 was −₹1.72 Cr, and −₹2.83 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−1.26.
Vivo Bio Tech reported borrowings of ₹67.42 Cr at Mar 2026, against cash and equivalents of ₹1.43 Cr.
Cash from operations was ₹34.94 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹2.52 Cr.